print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
12/09/2014 (Added to site)
Author(s): Valerio, M.; Stricker, P. D.; Ahmed, H. U.; Dickinson, L.; Ponsky, L.; Shnier, R.; Allen, C.; Emberton, M.

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer

Journal: Prostate Cancer and Prostatic Diseases, XX/X (2014), pp. 1-5
DOI: 10.1038/pcan.2014.33
Request reprint  |  Tell your friend  | 

Abstract:

Background: To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate.

Methods: We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametric magnetic resonance imaging (mpMRI) and targeted and/or template biopsy. IRE was delivered under transrectal ultrasound guidance with two to six electrodes positioned transperineally within the cancer lesion. Complications were recorded and scored accordingly to the NCI Common Terminology Criteria for Adverse Events; the functional outcome was physician reported in all patients with at least 6 months follow-up. A contrast-enhanced MRI 1 week after the procedure was carried out to assess treatment effect with a further mpMRI at 6 months to rule out evidence of residual visible cancer.

Results: Overall, 34 patients with a mean age of 65 years (s.d.=±6) and a median PSA of 6.1 ng ml-1 (interquartile range (IQR)= 4.3–7.7) were included. Nine (26%), 24 (71%) and 1 (3%) men had low, intermediate and high risk disease, respectively (D’Amico criteria). After a median follow-up of 6 months (range 1–24), 12 grade 1 and 10 grade 2 complications occurred. No patient had grade >/= 3 complication. From a functional point of view, 100% (24/24) patients were continent and potency was preserved in 95% (19/20) men potent before treatment. The volume of ablation was a median 12 ml (IQR = 5.6–14.5 ml) with the median PSA after 6 months of 3.4 ng ml-1 (IQR=1.9–4.8 ng ml-1). MpMRI showed suspicious residual disease in six patients, of whom four (17%) underwent another form of local treatment.

Conclusions: Focal IRE has a low toxicity profile with encouraging genito-urinary functional outcomes. Further prospective development studies are needed to confirm the functional outcomes and to explore the oncological potential.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: